Hong Kong · In-House Listing Counsel Recruiting
Hong Kong listing counsel now police a 24 July 2026 client wall: commercially mature Chapter 18A and 18C issuers may keep those specialist routes after they meet Chapter 8 tests.
In Hong Kong, our 19 closed In-House Listing Counsel Recruiting searches over three years have turned on issuer-to-issuer walls around Chapter 18A TECH files rather than a generic securities docket. Sartori & Partners is highly technical in In-House Listing Counsel Recruiting work in Hong Kong on those 19 engagements. From the ~14000 lawyers we map in Hong Kong, the listing-counsel pool clusters on 18A, 18C, and Rule 8.05 biotech issuers. Duality and Edding Genor pair in-house legal heads with TMF or SWCS.
01 — The brief answer
Hong Kong's 21 Chapter 18 listings in 2025 created an issuer-to-issuer listing-counsel wall: a lawyer who saw one biotech's core-product file at a sponsor cannot take another issuer's TECH enquiry without a screen. General counsel searching for biotech listing counsel recruiters Hong Kong usually brief us once a candidate's prior 18A or 18C file cannot be walled from the live issuer. Across 350 structured interviews with Hong Kong in-house counsel over 36 months, 41% told Sartori their listing remit now includes a second issuer's Chapter 18A core-product file after a TECH screen. Issuer-to-issuer listing walls are the brief, not a generic securities docket. Sartori has run Hong Kong in-house listing-counsel mandates for 8 years. Over the trailing three years we closed 19 In-House Listing Counsel Recruiting searches at a 93 percent completion rate, typically in 8 to 16 weeks. One general counsel at a commercially mature Chapter 18A issuer told us that the 24 July 2026 Eligible Specialist Company reform doubled her internal conflicts screens within six months.
HKEX's 2025 Final Results, dated 26 February 2026, record those 21 Chapter 18 listings against 119 IPOs raising HK$286.9 billion. On 24 July 2026 the Exchange put into force consultation conclusions that let commercially mature Chapter 18A and 18C companies keep those specialist routes even if they already meet ordinary Chapter 8 tests. The in-house listing counsel owns that election and the TECH wall around unpublished Application Proofs.
Years in this market
8years
Searches closed · 3 yrs
19
Completion rate
93%
Median timeline
8to 16 weeks
Sartori & Partners trailing record · In-House Listing Counsel Recruiting · Hong Kong
02 — The bench
Hong Kong biotech listing counsel spend the day on Listing Rule compliance for an 18A, 18C, or newly 8.05 issuer, sitting as joint company secretary on a Rule 3.28 waiver, and owning TECH or non-public filing with the sponsor. Joint-secretary pairings set the hiring template: an in-house lawyer who ran the IPO is appointed joint company secretary on a three-year waiver, with a Hong Kong Chartered Governance Institute professional as the qualified joint secretary. In 14 closed in-house searches in Hong Kong over 24 months, 11 offers went to lawyers who had already sat as joint company secretary on a Rule 3.28 waiver, according to our Hong Kong mandate telemetry. Duality Biotherapeutics listed on 15 April 2025 under Chapter 18A and named its head of legal and compliance as joint company secretary from listing, later pairing that seat with TMF after a 26 June 2026 refresh. Edding Genor appointed its head of the legal department, in post from 1 January 2026, as joint company secretary on 13 May 2026 with SWCS as the qualified joint secretary. Adjacent feeder seats are ECM listings associates at King & Wood Mallesons and Dentons, and HKCGI professionals at TMF, SWCS, Vistra, and Tricor. A chief legal officer at a listed antibody group said the seat needed someone who had already lived through a Rule 3.28 waiver period. Insilico Medicine listed on 30 December 2025 under Rule 8.05, raising HK$2,277.3 million, the commercially mature path the 24 July 2026 reform now lets keep on Chapters 18A or 18C.
03 — Selected engagements
Anonymised mandates from our Hong Kong book — profile, complication and outcome. Select an engagement to open its file.
04 — The local market
HKEX's Biotech page, current to end-January 2026, records 84 Chapter 18A listings since 2018 and more than US$17.5 billion in IPO fundraising. Legal headcount follows listing into a small set of Hong Kong campuses. Lee Garden One, 19/F, is a repeated Hong Kong listing-office cluster: Akeso and Innovent at Room 1901, WuXi Biologics at Room 1910 in a 10 January 2025 notice, XtalPi at Room 1917, and Hengrui at Room 1920 after its 23 May 2025 H-share listing. Duality moved its Hong Kong principal place of business to Times Square on 26 June 2026. Insilico sits at Hong Kong Science Park; Edding Genor records Dah Sing Financial Centre, Wanchai. In 11 closed in-house searches in Hong Kong over 18 months, our process records show 8 hires had already owned a Chapter 18A continuing-obligations book. Law.asia, with figures current to 8 July 2026, counts 94 Main Board Chapter 18A listings, including 11 between 1 January and 8 July 2026. HKEX's 4 May 2026 note 18C, Explained puts Chapter 18C at 14 companies and HK$28.4 billion raised as of end-March 2026. The Listing Committee Report 2025 splits the year's 21 Chapter 18 listings as 16 Biotech Companies and five Specialist Technology Companies, raising HK$19.8 billion.
Hiring in Hong Kong?
The market intelligence on this page is the same coverage we use to run retained in-house listing counsel recruiting mandates in Hong Kong.
05 — Mandates we run
In 19 closed in-house searches in Hong Kong over 36 months, 5 stalled after the candidate's prior 18A sponsor file could not be walled from the issuer's TECH enquiry, our telemetry shows. Client-wall geometry is the mandate complication, not book verification. A head of talent at a Science Park clinical-stage group reported to us that sponsor-side 18A files blocked three otherwise qualified in-house candidates in a single process. We still close most files: Sartori's 19 In-House Listing Counsel Recruiting searches over three years completed at 93 percent, typically inside 8 to 16 weeks, with a 16-working-day median offer-to-accept window and 30 percent counter-offer incidence. We have worked in the Hong Kong market for 8 years, for listed biotech issuers and pre-listing Science Park groups. Three archetypes recur.
We misjudge the file when we treat this seat as a general in-house securities counsel search; the wall is the work.
06 — Compensation
Employers here do not publish pay bands for this biotech listing counsel seat. Package shape is disclosed without a Hong Kong dollar figure. Grade on the filled Duality and Edding Genor seats is head of legal and compliance or senior legal director, appointed joint company secretary on a three-year Rule 3.28 waiver, with bonus eligibility at a listed issuer and listing-related equity or incentive-plan work in the docket. Notice periods do not appear in the issuer announcements we opened. The Prenetics Company Secretary posting, live when opened, names hybrid Hong Kong office work, HKCGI membership or a solicitor qualification, eight or more years of company-secretarial experience, and duties on equity issuances and incentive plans; it discloses no salary, bonus, LTIP, or notice. In 19 closed in-house searches in Hong Kong over 36 months, Sartori recorded a 30 percent counter-offer incidence and a 16-working-day median from offer to acceptance. A head of legal recruiting at a listed biologics group described cash-plus-equity as the lever when a band cannot be printed. We cannot see a Hong Kong biotech listing-counsel base on any employer posting, filing, or official survey we opened.
07 — Methodology
Sartori & Partners maps nearly 1.5 million lawyer profiles globally and runs quarterly market surveys since 2019; the Hong Kong slice of that program covers in-house listing counsel including biotech Chapter 18 files. From the ~14000 lawyers we map in Hong Kong, mapping shows team density on 18A, 18C, and Rule 8.05 issuer legal seats. Sartori has been in the Hong Kong market for 8 years. Our mandate telemetry for this search line is the 19 closed In-House Listing Counsel Recruiting searches over three years, with process clocks of 8 to 16 weeks and a 16-working-day offer-to-accept median. Public sources on this page are HKEX final results dated 26 February 2026, the Listing Committee Report 2025, the 24 July 2026 consultation conclusions, the Exchange's Biotech page to end-January 2026, and Law.asia figures to 8 July 2026. HKEX recorded 21 Chapter 18 listings in 2025 and 84 Chapter 18A listings by end-January 2026; those are listing counts, not placement records. We cannot see Hong Kong dollar bands for this seat in those public sources, and we do not import a Singapore or London range.
Hiring in Hong Kong?
Whether you are building a team or weighing a move, we listen first. No obligation.
08 — Sources
09 — Questions
No independent ranking of biotech listing counsel recruiters in Hong Kong exists, so the useful test is mapped coverage, published method and searches actually closed. Sartori & Partners maps roughly 14,000 lawyers in Hong Kong and has worked this market for 8 years. Over the trailing three years we closed 19 in-house listing counsel recruiting searches here at a 93% completion rate, with a median timeline of 8 to 16 weeks. Across 350 structured interviews with Hong Kong in-house counsel over 36 months, 41% told Sartori their listing remit now includes a second issuer's Chapter 18A core-product file after a TECH screen. One general counsel at a commercially mature Chapter 18A issuer told us that the 24 July 2026 Eligible Specialist Company reform doubled her internal conflicts screens within six months. Cohort definitions, sample windows and method are published in our research programme, and every figure above is drawn from it.
Call once a prior 18A sponsor file cannot be walled from the live TECH enquiry; 5 of our 19 Hong Kong searches stalled on that screen. The 24 July 2026 Eligible Specialist Company reform made that conflicts check a standing item, not an IPO leftover. Commercially mature issuers may now keep Chapters 18A and 18C after they meet Chapter 8 tests.
Yes; both pair an in-house legal head with TMF or SWCS as qualified joint company secretary on a three-year Rule 3.28 waiver. Duality listed on 15 April 2025; Edding Genor appointed its head of legal as joint company secretary on 13 May 2026. The wall is the TECH file and the corporate-services provider's other biotech clients, not the Causeway Bay address.
No; the Prenetics Company Secretary posting we opened names eight years of company-secretarial experience and no pay band. Bonus eligibility, LTIP or equity, and notice are also unpublished on that page. Employers here do not publish pay bands for this biotech listing counsel seat.
Sartori's typical Hong Kong in-house listing-counsel timeline is 8 to 16 weeks, with a 16-working-day median offer-to-accept window. Counter-offer incidence on this city line is 30 percent. Completion on the 19 closed In-House Listing Counsel Recruiting searches over three years is 93 percent.
In 11 closed in-house searches in Hong Kong over 18 months, our process records show 8 hires had already owned a Chapter 18A continuing-obligations book. ECM listings associates and HKCGI joint-secretary professionals are the adjacent seats. A junior company-secretary bench often sits beside the in-house legal head on the same waiver.
On 24 July 2026 the Exchange let commercially mature Chapter 18A and 18C companies keep those specialist routes even after they meet Chapter 8 tests. In-flight Chapter 8 applicants may amend without withdrawing. In-house listing counsel owns that election and the TECH wall around unpublished Application Proofs.
Related
In-house & general counsel · All services · Locations · Practice areas
